Incidence of serious gastrointestinal events among tildrakizumab‐treated patients with psoriasis: Letter to the Editor

por Gooderham, M., Elewski, B.E., Pariser, D.M., Sofen, H., Mendelsohn, A.M., Rozzo, S.J., Li, Q.
Publicado 2019

Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase‐3, randomized, placebo‐controlled trial

por Elewski, B.E., Baker, C.S., Crowley, J.J., Poulin, Y., Okun, M.M., Calimlim, B., Geng, Z., Reyes Servin, O., Rich, P.A.
Publicado 2019

Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phas...

por Silverberg, J.I., Toth, D., Bieber, T., Alexis, A.F., Elewski, B.E., Pink, A.E., Hijnen, D., Jensen, T.N., Bang, B., Olsen, C.K., Kurbasic, A., Weidinger, S.
Publicado 2021